Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

The user is using topical finasteride, Bioscalin, Omega 3, and hair filler therapy for hair loss. There is some progress noted, but varying photo angles and lighting make it hard to assess fully.

The user is experiencing significant hair regrowth using 1mg oral finasteride, 1.25mg oral minoxidil, 5% topical minoxidil, biotin, vitamin D3, fish oil, and weekly microneedling with a 1mm needle roller. They report no major side effects, except for slight hair growth near the eyebrows, and are pleased with the progress.

A user shared their hair regrowth progress using oral finasteride, biotin, topical minoxidil, and DS thickening shampoo over five months, reporting significant improvements in hair texture and growth. They experienced minor side effects like a slight headache from switching minoxidil forms but noted no issues with finasteride.

The user is pleased with their hair growth progress after 5 months of using Minoxidil, Finasteride, and RU58841, and is curious if the baby hairs at the temple will fully connect with the rest of the hair. It's uncertain if the connection will happen yet.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

The post discusses a hair loss treatment regimen including oral finasteride, topical minoxidil, a rejuvenating scalp serum with caffeine, rosemary, and ginger, topical ketoconazole, saw palmetto, and derma rolling. The user seeks advice for scalp pimples and irritation.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

The conversation is about hair regrowth using high-dose dutasteride, oral minoxidil, and microneedling. Users discuss seeing tiny hairs and hope they will become terminal, with advice to use derma rolling weekly for better results.

A user's 18-month hairline progress using minoxidil, finasteride, Nizoral, microneedling, and scalp massage. They share their routine and discuss treatment effectiveness and photo order confusion.

The user experienced significant hairline regrowth over seven months using oral finasteride, topical minoxidil, and microneedling. Initial shedding occurred, but baby hairs appeared around three months, gradually maturing to fill in the hairline.

The user shared progress photos of hair regrowth using copper peptides and NAD+ over five months. Another user commented on the lighting, and another praised the progress.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Hair loss discussion includes treatments like Minoxidil, finasteride, and RU58841. Platelet rich plasma treatment is considered expensive but cheaper than hair transplant.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

The user experienced hair regrowth using finasteride, minoxidil, biotin, iron, microneedling, and caffeine shampoo over four months. They plan to continue treatment for fuller results by month 6 or 7.

A user's personal hair loss progress with treatments, including finasteride (1.25mg), minoxidil, needling, and Nizoral; and advice from other users on how to perform the needling correctly.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.